Antigen Receptors Gene Analysis for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia: The Role of High Throughput Sequencing
The prognosis of adult acute lymphoblastic leukemia (ALL) is variable but more often dismal. Indeed, its clinical management is challenging, current therapies inducing complete remission in 65–90% of cases, but only 30–40% of patients being cured. The major determinant of treatment failure is relaps...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Hemato |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-6357/4/1/4 |
| _version_ | 1797611486944690176 |
|---|---|
| author | Pier Paolo Piccaluga Stefania Paolini Giuseppe Visani |
| author_facet | Pier Paolo Piccaluga Stefania Paolini Giuseppe Visani |
| author_sort | Pier Paolo Piccaluga |
| collection | DOAJ |
| description | The prognosis of adult acute lymphoblastic leukemia (ALL) is variable but more often dismal. Indeed, its clinical management is challenging, current therapies inducing complete remission in 65–90% of cases, but only 30–40% of patients being cured. The major determinant of treatment failure is relapse; consequently, measurement of residual leukemic blast (minimal residual disease, MRD) has become a powerful independent prognostic indicator in adults. Numerous evidences have also supported the clinical relevance of MRD assessment for risk class assignment and treatment selection. MRD can be virtually evaluated in all ALL patients using different technologies, such as polymerase chain reaction amplification of fusion transcripts and clonal rearrangements of antigen receptor genes, flow cytometric study of leukemic immunophenotypes and, the most recent, high throughput sequencing (HTS). In this review, the authors focused on the latest developments on MRD monitoring with emphasis on the use of HTS, as well as on the clinical impact of MRD monitoring. |
| first_indexed | 2024-03-11T06:29:28Z |
| format | Article |
| id | doaj.art-d3019bc2832b46189845ecba1a59e474 |
| institution | Directory Open Access Journal |
| issn | 2673-6357 |
| language | English |
| last_indexed | 2024-03-11T06:29:28Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Hemato |
| spelling | doaj.art-d3019bc2832b46189845ecba1a59e4742023-11-17T11:22:21ZengMDPI AGHemato2673-63572023-01-0141425510.3390/hemato4010004Antigen Receptors Gene Analysis for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia: The Role of High Throughput SequencingPier Paolo Piccaluga0Stefania Paolini1Giuseppe Visani2Biobank of Research and Institute of Hematology and Medical Oncology “L. and A. Seràgnoli”, IRCCS Azienda Opedaliera-Universitaria S. Orsola-Malpighi Hospital, 40138 Bologna, ItalyBiobank of Research and Institute of Hematology and Medical Oncology “L. and A. Seràgnoli”, IRCCS Azienda Opedaliera-Universitaria S. Orsola-Malpighi Hospital, 40138 Bologna, ItalyHematology and Hematopoietic Stem Cell Transplant Center, AORMN, 61121 Pesaro, ItalyThe prognosis of adult acute lymphoblastic leukemia (ALL) is variable but more often dismal. Indeed, its clinical management is challenging, current therapies inducing complete remission in 65–90% of cases, but only 30–40% of patients being cured. The major determinant of treatment failure is relapse; consequently, measurement of residual leukemic blast (minimal residual disease, MRD) has become a powerful independent prognostic indicator in adults. Numerous evidences have also supported the clinical relevance of MRD assessment for risk class assignment and treatment selection. MRD can be virtually evaluated in all ALL patients using different technologies, such as polymerase chain reaction amplification of fusion transcripts and clonal rearrangements of antigen receptor genes, flow cytometric study of leukemic immunophenotypes and, the most recent, high throughput sequencing (HTS). In this review, the authors focused on the latest developments on MRD monitoring with emphasis on the use of HTS, as well as on the clinical impact of MRD monitoring.https://www.mdpi.com/2673-6357/4/1/4acute lymphoblastic leukemiaminimal residual diseasenext generation sequencingtargeted therapyantigen receptorIGVH |
| spellingShingle | Pier Paolo Piccaluga Stefania Paolini Giuseppe Visani Antigen Receptors Gene Analysis for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia: The Role of High Throughput Sequencing Hemato acute lymphoblastic leukemia minimal residual disease next generation sequencing targeted therapy antigen receptor IGVH |
| title | Antigen Receptors Gene Analysis for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia: The Role of High Throughput Sequencing |
| title_full | Antigen Receptors Gene Analysis for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia: The Role of High Throughput Sequencing |
| title_fullStr | Antigen Receptors Gene Analysis for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia: The Role of High Throughput Sequencing |
| title_full_unstemmed | Antigen Receptors Gene Analysis for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia: The Role of High Throughput Sequencing |
| title_short | Antigen Receptors Gene Analysis for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia: The Role of High Throughput Sequencing |
| title_sort | antigen receptors gene analysis for minimal residual disease detection in acute lymphoblastic leukemia the role of high throughput sequencing |
| topic | acute lymphoblastic leukemia minimal residual disease next generation sequencing targeted therapy antigen receptor IGVH |
| url | https://www.mdpi.com/2673-6357/4/1/4 |
| work_keys_str_mv | AT pierpaolopiccaluga antigenreceptorsgeneanalysisforminimalresidualdiseasedetectioninacutelymphoblasticleukemiatheroleofhighthroughputsequencing AT stefaniapaolini antigenreceptorsgeneanalysisforminimalresidualdiseasedetectioninacutelymphoblasticleukemiatheroleofhighthroughputsequencing AT giuseppevisani antigenreceptorsgeneanalysisforminimalresidualdiseasedetectioninacutelymphoblasticleukemiatheroleofhighthroughputsequencing |